JPWO2020202111A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020202111A5 JPWO2020202111A5 JP2021559187A JP2021559187A JPWO2020202111A5 JP WO2020202111 A5 JPWO2020202111 A5 JP WO2020202111A5 JP 2021559187 A JP2021559187 A JP 2021559187A JP 2021559187 A JP2021559187 A JP 2021559187A JP WO2020202111 A5 JPWO2020202111 A5 JP WO2020202111A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- use according
- drug
- vector
- sufficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 66
- 229940079593 drug Drugs 0.000 claims 25
- 230000000590 parasiticidal effect Effects 0.000 claims 12
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims 11
- 244000052769 pathogen Species 0.000 claims 10
- 208000011312 Vector Borne disease Diseases 0.000 claims 9
- 239000002297 parasiticide Substances 0.000 claims 8
- 238000011287 therapeutic dose Methods 0.000 claims 8
- 208000036142 Viral infection Diseases 0.000 claims 7
- 230000009385 viral infection Effects 0.000 claims 7
- 230000009885 systemic effect Effects 0.000 claims 6
- FLEFKKUZMDEUIP-QFIPXVFZSA-N 1-[6-[(5s)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3C[C@](ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-QFIPXVFZSA-N 0.000 claims 5
- MLBZKOGAMRTSKP-UHFFFAOYSA-N fluralaner Chemical compound C1=C(C(=O)NCC(=O)NCC(F)(F)F)C(C)=CC(C=2CC(ON=2)(C=2C=C(Cl)C=C(Cl)C=2)C(F)(F)F)=C1 MLBZKOGAMRTSKP-UHFFFAOYSA-N 0.000 claims 5
- 229960004498 fluralaner Drugs 0.000 claims 5
- 230000001717 pathogenic effect Effects 0.000 claims 5
- 229960005393 sarolaner Drugs 0.000 claims 5
- 241000224016 Plasmodium Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 201000004792 malaria Diseases 0.000 claims 4
- -1 rotiranel Chemical compound 0.000 claims 4
- BPFUIWLQXNPZHI-UHFFFAOYSA-N 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-N-[(methoxyamino)methylidene]-2-methylbenzamide Chemical compound C1=C(C)C(C(=O)N\C=N/OC)=CC=C1C1=NOC(C(F)(F)F)(C=2C=C(Cl)C=C(Cl)C=2)C1 BPFUIWLQXNPZHI-UHFFFAOYSA-N 0.000 claims 3
- 208000025721 COVID-19 Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- WLSQDEYDCAGPIR-UHFFFAOYSA-N isocycloseram Chemical compound O=C1N(CC)OCC1NC(=O)C1=CC=C(C=2CC(ON=2)(C=2C=C(Cl)C(F)=C(Cl)C=2)C(F)(F)F)C=C1C WLSQDEYDCAGPIR-UHFFFAOYSA-N 0.000 claims 3
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims 2
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 claims 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 2
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 2
- 241000865041 Dermacentor occidentalis Species 0.000 claims 2
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 claims 2
- 201000005804 Eastern equine encephalitis Diseases 0.000 claims 2
- 206010014587 Encephalitis eastern equine Diseases 0.000 claims 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims 2
- 229950000971 baricitinib Drugs 0.000 claims 2
- 229960003677 chloroquine Drugs 0.000 claims 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 2
- 229960005107 darunavir Drugs 0.000 claims 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 2
- 229950008454 favipiravir Drugs 0.000 claims 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960004525 lopinavir Drugs 0.000 claims 2
- 229960001962 mefloquine Drugs 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims 2
- 229960004626 umifenovir Drugs 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- 241000690120 Borrelia mayonii Species 0.000 claims 1
- 241000216520 Borrelia miyamotoi Species 0.000 claims 1
- 241000181212 Bourbon virus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000003917 Dirofilariasis Diseases 0.000 claims 1
- 241000605314 Ehrlichia Species 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 206010014614 Encephalitis western equine Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 241001335250 Heartland virus Species 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 241000223801 Plasmodium knowlesi Species 0.000 claims 1
- 241001505293 Plasmodium ovale Species 0.000 claims 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 claims 1
- 241000223810 Plasmodium vivax Species 0.000 claims 1
- 241001495398 Rickettsia parkeri Species 0.000 claims 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 claims 1
- 208000035056 Tick-Borne disease Diseases 0.000 claims 1
- 208000034784 Tularaemia Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 claims 1
- 201000005806 Western equine encephalitis Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 208000001455 Zika Virus Infection Diseases 0.000 claims 1
- 201000004296 Zika fever Diseases 0.000 claims 1
- 208000006730 anaplasmosis Diseases 0.000 claims 1
- 201000008680 babesiosis Diseases 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 208000000292 ehrlichiosis Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 208000016523 tick-borne infectious disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962829573P | 2019-04-04 | 2019-04-04 | |
| US62/829,573 | 2019-04-04 | ||
| PCT/IB2020/053229 WO2020202111A1 (en) | 2019-04-04 | 2020-04-03 | Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527359A JP2022527359A (ja) | 2022-06-01 |
| JPWO2020202111A5 true JPWO2020202111A5 (enExample) | 2023-04-10 |
Family
ID=72667108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559187A Pending JP2022527359A (ja) | 2019-04-04 | 2020-04-03 | 媒介動物媒介性疾患およびウイルス性疾患の治療または予防のための全身性イソキサゾリン系寄生虫駆除剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220160682A1 (enExample) |
| EP (1) | EP3946325A4 (enExample) |
| JP (1) | JP2022527359A (enExample) |
| KR (1) | KR20220054241A (enExample) |
| CN (1) | CN113993518A (enExample) |
| AU (1) | AU2020251960A1 (enExample) |
| BR (1) | BR112021019931A2 (enExample) |
| CA (1) | CA3136042A1 (enExample) |
| IL (1) | IL286914A (enExample) |
| MX (1) | MX2021012188A (enExample) |
| WO (1) | WO2020202111A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| KR20200111177A (ko) | 2017-12-15 | 2020-09-28 | 타르서스 파마수티칼스, 아이엔씨. | 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법 |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| CN111265528A (zh) | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 法匹拉韦在治疗冠状病毒感染方面的应用 |
| WO2022079496A1 (en) * | 2020-10-13 | 2022-04-21 | Menschlich Healthcare Opc Private Limited | A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof |
| CN112294793B (zh) * | 2020-10-21 | 2022-03-22 | 青岛海洋生物医药研究院股份有限公司 | 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用 |
| WO2022130031A1 (en) * | 2020-12-17 | 2022-06-23 | Chander Mohan Negi | A pharmaceutical composition of nitazoxanide and mefloquine and method thereof |
| CN118420621A (zh) * | 2021-02-07 | 2024-08-02 | 南京知和医药科技有限公司 | 一种磺酰胺类多环化合物及其制备方法与用途 |
| JP2025517707A (ja) * | 2022-05-16 | 2025-06-10 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 蚊の防除の方法 |
| WO2024168149A1 (en) * | 2023-02-10 | 2024-08-15 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| US11903962B1 (en) * | 2023-05-07 | 2024-02-20 | Michael Farber | Isoxazoline complexes and compositions thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI556741B (zh) * | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| US8313752B2 (en) * | 2009-04-14 | 2012-11-20 | Merial Limited | Macrocyclic lactone combination compositions, vaccines and methods for producing same |
| WO2018081733A1 (en) * | 2016-10-31 | 2018-05-03 | The California Institute For Biomedical Research | Methods and compositions for preventing vector-borne disease transmission |
| HRP20241712T1 (hr) * | 2018-09-05 | 2025-02-14 | Zoetis Services Llc | Antiparazitske formulacije prihvatljivog okusa |
| CA3146043A1 (en) * | 2019-07-22 | 2021-01-28 | Intervet International B.V. | Soft chewable veterinary dosage form |
-
2020
- 2020-04-03 KR KR1020217036211A patent/KR20220054241A/ko active Pending
- 2020-04-03 AU AU2020251960A patent/AU2020251960A1/en active Pending
- 2020-04-03 WO PCT/IB2020/053229 patent/WO2020202111A1/en not_active Ceased
- 2020-04-03 JP JP2021559187A patent/JP2022527359A/ja active Pending
- 2020-04-03 EP EP20784367.3A patent/EP3946325A4/en active Pending
- 2020-04-03 MX MX2021012188A patent/MX2021012188A/es unknown
- 2020-04-03 BR BR112021019931A patent/BR112021019931A2/pt unknown
- 2020-04-03 US US17/594,144 patent/US20220160682A1/en not_active Abandoned
- 2020-04-03 CN CN202080041597.8A patent/CN113993518A/zh active Pending
- 2020-04-03 CA CA3136042A patent/CA3136042A1/en active Pending
-
2021
- 2021-10-03 IL IL286914A patent/IL286914A/en unknown
-
2023
- 2023-03-15 US US18/184,513 patent/US20230218584A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11072648B2 (en) | Mast cell stabilizers for treatment of fever | |
| JP7559175B6 (ja) | Ｈｉｖおよびエイズの治療および予防方法 | |
| Zhang et al. | Current targeted therapeutics against COVID-19: based on first-line experience in China | |
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| JP2017514911A5 (enExample) | ||
| JPWO2020202111A5 (enExample) | ||
| JPWO2023054732A5 (enExample) | ||
| CN113633649B (zh) | 瑞德西韦及其核苷的组合制剂在抗猪流行性腹泻病毒中的应用 | |
| US20140275139A1 (en) | Mdr method and products for treating hiv/aids | |
| Naik et al. | Therapeutic Strategies in the Management of COVID-19 | |
| US20100015248A1 (en) | Pharmaceutical composition | |
| KR20050085681A (ko) | 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도 | |
| JP2006511538A5 (enExample) | ||
| TW201842911A (zh) | 治療療法 | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| TWI282735B (en) | Combination and pharmaceutical formulation for the treatment of HBV infection | |
| RU2021129948A (ru) | Системные изоксазолиновые паразитициды для лечения или профилактики трансмиссивных и вирусных заболеваний | |
| Mohammed et al. | Drug repositioning for the prophylaxis and treatment of COVID-19 | |
| CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
| JPH06505733A (ja) | ミクロスポリディア症の治療におけるベンゾイミダゾール駆虫薬の使用 | |
| Al-Noaemi Mohammed et al. | Drug Repositioning For The Prophylaxis And Treatment of COVID-19 | |
| WO2022019742A1 (es) | Paquete farmaceutico para prevención y/o tratamiento de enfermedad por covid-19 y uso del mismo | |
| JP2006008540A (ja) | 風邪薬 | |
| WO1999025351A1 (fr) | Compositions pharmaceutiques antipaludiques | |
| Chopra et al. | Studies on the Action of Synthetic Antimalarial Drugs on Indian Strains of Malaria: Cilional in the Treatment of'Crescent Carriers' |